Clinical Trial Update: Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

View source ↗

Summary

A completed post-marketing surveillance study in Japan evaluating durvalumab for non-small cell lung cancer under the Imfinzi/Imjudo brands.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• IMJUDO (TREMELIMUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Status: COMPLETED